Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Essel Corporate to acquire 1.15% stake in Zee Entertainment

2018-07-20 thehindubusinessline
Essel Corporate LLP plans to acquire 1.1 crore shares, or 1.15 per cent stake, of Zee Entertainment Enterprises (ZEEL) from Essel International, another promotor group entity, at an estimated price of over Rs 610 crore.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Bharat Kedia is COO at Motilal PE

2018-07-18 thehindubusinessline
SME-focussed investment firm Motilal Oswal Private Equity Investment Advisors (MOPE) has appointed Bharat Kedia as Chief Operating Officer, who was previously with Zee Entertainment Enterprises as Chief Financial Officer. In addition, he has worked in firms such as Parag Milk Foods, Publicis Groupe India, Coca-Cola HBC SA, United Beverages, BDH Industries and Kansai Nerolac Paints, earlier in his career.
CCHGY 524828 CCH KANSAINER ZEEEY KNZAY 505537 BDH ZEEL 500165

0
Zee Entertainment Enterprises Limited - Shareholders meeting

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Outcome of Board Meeting

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Financial Result Updates

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Ashok Leyland, ICICI Lombard results

2018-07-16 thehindubusinessline
Nearly two dozen companies, including 8K Miles Software Services, Ashok Leyland, Atishay, Crisil, Federal Bank, Goa Carbon, Hindustan Media Ventures, ICICI Lombard General Insurance, Integrated Capital, Jindal Stainless, Indian Metals & Ferro Alloys, Muthoot Capital Services, Nucleus Software Exports, Rallis India, Sintex Industries, Tata Sponge Iron and Zee Entertainment Enterprises will declare their April-June quarter results on Tuesday.
RALLIS GOACARBON 500469 IDBI 531209 MUTHTFN FEDA TATASPONGE FEDS 500355 JSL 500477 ZEEL FEDERALBNK 509567 ASHOKLEY 513010 500116 IBN 532508 FDBAY FERROALL AKLD 533217 511766 ICICIBANK ZEEEY 532174 SINTEX 502742 505537 500141 AKLS NUCLEUS HMVL

0
Zee Entertainment Enterprises Limited - Disclosure under SEBI Takeover Regulations

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Essel Corporate to acquire 1.5 cr shares of Zee Entertainment

2018-07-14 thehindubusinessline
Essel Corporate LLP (formerly known as AIIore Enterprises LLP) has informed the stock exchanges that it proposes to acquire 1.5 crore shares of Zee Entertainment Enterprises Ltd (ZEEL).
ZEEEY 505537 ZEEL

0
Zee Entertainment stock falls 2% after Macquarie cuts target price on rising uncertainty

2018-07-13 moneycontrol
Zee Entertainment Enterprises share price fell more than 2 percent on Friday after global brokerage house Macquarie slashed target price on the stock on rising uncertainty.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Trading Window

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

0
Zee Entertainment Enterprises Limited - Shareholders meeting

2018-06-26 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
ZEEEY 505537 ZEEL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...